Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

NEW YORK – Novartis on Thursday announced it has acquired Kate Therapeutics to bolster its capabilities to develop gene therapies for inherited neuromuscular diseases. In the transaction valued at ...

Pentixapharm said on Thursday it has begun treating patients in a Phase I/II trial of its radiopharmaceutical therapy Lu177-PentixaTher in adult patients with relapsed or refractory CXCR4-positive ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.

The firm will test the activity of NEU-411 in patients with Parkinson's caused by LRRK2 mutations or whose disease is influenced by LRRK2 overactivity.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) as a treatment for advanced HER2-positive biliary tract cancer.

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The company said it expects to seek regulatory permission to begin clinical testing of VY1706 in the US and Canada in 2026.

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.